title: [Effect of granulocyte colony stimulating factor (G-CSF) on peripheral blood leukocytes and lymphocytes in patients with chemotherapy-induced leukopenia].
abstract: In patients with extensive chemotherapy, G-CSF abrogated leukopenia following administration of cytotoxic agents. Six women with ovarian cancer and chemotherapy-induced leukopenia received 300 micrograms Filgrastrim (r-metHuG-CSF, Neupogen 30; AMGEN, Germany) daily for 10 days. Leukocytes and lymphocyte subsets of peripheral blood were determined before, throughout and after subcutaneous injections of G-CSF by flow cytometry using monoclonal antibodies to CD3, CD4, CD8, CD14, CD16/56, CD19 and CD45. It could be observed that not only neutrophils (23 fold) but also lymphocytes (6 fold) and monocytes (10 fold) showed a dramatic increase in cell counts throughout and after G-CSF administration. This is in contrast to previous reports, where only effects on neutrophils were described. In spite of the increase in lymphocytes the relative percentage of CD3+, CD19+, CD3-CD16/CD56+, CD3+, CD8+ and CD3+ CD4+ lymphocyte subsets did not change throughout and after therapy, except for an increased expression of HLA-DR on CD3+ lymphocytes.
authors.affiliation: Klinik für Frauenheilkunde und Geburtshilfe, Universität Magdeburg.
authors.forename: M
authors.initials: M
authors.lastname: Böhme
authors.forename: D
authors.initials: D
authors.lastname: Schmidt
authors.forename: J
authors.initials: J
authors.lastname: Radke
authors.forename: J
authors.initials: J
authors.lastname: Morenz
authors.forename: W
authors.initials: W
authors.lastname: Weise
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage*; D006801:Humans; D016130:Immunophenotyping; D007279:Injections, Subcutaneous; D007958:Leukocyte Count / Q000187:drug effects*; D007970:Leukopenia / Q000139:chemically induced* / Q000628:therapy; D018655:Lymphocyte Count / Q000187:drug effects*; D016131:Lymphocyte Subsets / Q000187:drug effects* / Q000276:immunology; D009000:Monocytes / Q000187:drug effects; D009504:Neutrophils / Q000187:drug effects; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000276:immunology; D011994:Recombinant Proteins / Q000008:administration & dosage
chemical_list: D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D000069585:Filgrastim; D002945:Cisplatin